肺瘤平膏及其联合不同类别药物对肺转移微环境中PI3K/AKT/NF-κB表达的研究  

Research of Feiliuping Gao and its combination with different types of drugs intervention on expression of PI3K/AKT/NF-κB in lung metastatic microenvironment

作　　者：刘瑞[1,2] 郑红刚 李卫东[1] 花宝金[1] 姚博[3] 齐鑫 裴迎霞[1] 张芸[1] LIU Rui;ZHENG Hong-gang;LI Wei-dong;HUA Bao-jin;YAO Bo;QI Xin;PEI Ying-xia;ZHANG Yun(Department of Oncology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Cancer Institute of Beijing Guang'an Chinese Medicine,Beijing 100050,China;Heilongjiang University of Chinese Medicine,Harbin 150040,China)

机构地区：[1]中国中医科学院广安门医院肿瘤科,北京100053 [2]北京广安中医肿瘤研究院,北京100050 [3]黑龙江中医药大学,黑龙江哈尔滨150040

出　　处：《中国中药杂志》2018年第19期3913-3918,共6页China Journal of Chinese Materia Medica

基　　金：国家科技部重点领域创新团队项目(RA20134022);国家自然科学基金项目(81603601,81273718);中国中医科学院肿瘤扶正培本创新团队项目(YS1305)

摘　　要：观察肺瘤平膏及其联合不同类别药物(塞来昔布、环磷酰胺)对肺转移微环境中PI3K/AKT/NF-κB表达的影响,揭示中药干预时间对肺转移微环境中关键分子的作用优势。建立Lewis肺癌移植瘤小鼠模型,分别在肺瘤平膏干预14,21,28 d收集肺组织,并通过免疫组化、Western blot法检测PI3K,AKT,NF-κB的表达。14 d时,与对照组比较,各组PI3K表达无明显差别,塞来昔布(CLB)组、肺瘤平膏+环磷酰胺(FLP+CTX)组、肺瘤平膏+塞来昔布(FLP+CLB)组均可明显抑制AKT蛋白表达(P<0.05),其中FLP+CLB组抑制AKT蛋白表达具有优势;FLP+CLB组可抑制NF-κB蛋白表达(P<0.05)。21 d时,与对照组比较,肺瘤平膏(FLP)组及FLP+CTX组可抑制PI3K表达(P<0.05),FLP+CLB组抑制PI3K表达的效果最佳(P<0.001);仅有FLP+CLB组可以明显抑制AKT蛋白表达(P<0.01);FLP+CTX组抑制NF-κB蛋白表达的效果最佳(P<0.001)。28 d时,与对照组比较,FLP+CLB组可抑制PI3K,AKT表达(P<0.001)。肺瘤平膏联合塞来昔布在调控肺转移微环境PI3K/AKT/NF-κB分子表达方面具有优势。The aim of this paper was to observe the effect of Feiliuping Gao and its combination with different types of drugs intervention on the expression of PI3 K/AKT/NF-κB in lung metastatic microenvironment, and to reveal the advantage of Chinese medicine intervention time on the key molecule in lung metastatic microenvironment. The mouse model of Lewis lung carcinoma was established, and lung tissues were collected at 14 days, 21 days and 28 days after the intervention of Feiliuping Gao, and the expressions of PI3 K, AKT and NF-κB were detected by immunohistochemistry and Western blot. At 14 days, there was no significant difference in PI3 K expression between each group and the control group. The expression of AKT protein was significantly inhibited in the celecoxib(CLB) group, the Feiliuping Gao(FLP) combination with cyclophosphamide(FLP+CTX) group, and the Feiliuping Gao combination with celecoxib(FLP+CLB) group(P<0.05). The inhibition of AKT protein expression in FLP+CLB group was superior. The FLP+CLB group can inhibit the expression of NF-κB protein(P<0.05). At 21 days, compared with the control group, the expression of PI3 K was inhibited in FLP group and the FLP+CTX group(P<0.05), while the expression of PI3 K was best inhibited in the FLP+CLB group(P<0.001). Only the FLP+CLB group could significantly inhibit the expression of AKT protein(P<0.01). The FLP+CTX group had the best effect in inhibiting the expression of NF-κB protein(P<0.001). At 28 days, compared with the control group, the expression of PI3 K and AKT was inhibited in the FLP+CLB group(P<0.001). Feiliuping ointment combination with celecoxib has an advantage in regulating the expression of PI3 K/AKT/NF-κB molecules in lung metastatic microenvironment.

关 键 词：中医药 转移微环境 肺瘤平膏 塞来昔布 PI3K 

分 类 号：R734.2[医药卫生—肿瘤]